ClinicalTrials.gg
RecruitingNCT06323213Updated Jan 7, 2026

Efficacy and Safety Study of 610 in Patients With Severe Asthma

A Phase 3 interventional study of 610 and Placebo in Asthma, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Planned enrollment
44th of 182
480 · median 203
Started
2024
with 37 others
Phase 3
47 of 251
13 open now
Primary completion
2027-02
later than 40 of 95 live
Registered
155th of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 44th largest by planned enrollment of the 182 interventional ones that give a count, is one of 38 that started in 2024, is one of 47 in phase 3, reaches primary completion later than 40 of the 95 other live ones, and was the 155th registered.

Asthma

4,849 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 416 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma.

Read the detailed description

The total duration of study per patient is approximately 66 weeks, including 6 weeks of screening period, 52 weeks of treatment period and 8 weeks of follow-up period.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to give written prior to participation in the study.
  2. Male or female adults ages 18 to 75 years old when signing the informed consent.
  3. Documented diagnosis of asthma for at least one year prior to screening.
  4. History of physician-diagnosed asthma requiring treatment with ICS and at least one other control medication for at least 6 months prior to screening.

Exclusion criteria

Exclusion Criteria:

  1. Presence of a known pre-existing, lung condition other than asthma.
  2. Severe asthma exacerbation within 4 weeks prior to randomization.
  3. Subjects with any eosinophilic diseases other than asthma.
  4. Known, pre-existing severe or clinically significant cardiovascular disease.
  5. known, pre-existing other concurrent clinically significant medical conditions that are uncontrolled with standard treatment.
  6. Subjects who have active , or infections as determined by positive results at Screening.
  7. Subjects with allergy/intolerance to a monoclonal antibody.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
480 participants (estimated)

Study arms

  • Experimental
    610 group

    Subjects will receive 610 for 52 weeks.

    Drug: 610

  • Placebo comparator
    placebo group

    Subjects will receive placebo for 52 weeks.

    Drug: Placebo

Interventions

  • Drug610

    610 subcutaneously injection.

  • DrugPlacebo

    Placebo subcutaneously injection.

06

What researchers measure

Primary outcomes

  1. Annualized rate of severe exacerbation events

    Annualized rate of severe exacerbation events during the 52-week placebo-controlled treatment period

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Time to first severe exacerbation event

    Time to first severe exacerbation event during the 52-week placebo-controlled treatment period

    Time frame: Up to 52 weeks

  2. Annualized rate of severe exacerbation events resulting in hospitalization or emergency room visit

    Annualized rate of severe exacerbation events resulting in hospitalization or emergency room visit during the 52-week placebo-controlled treatment period

    Time frame: Up to 52 weeks

  3. Change from baseline in ACQ score

    Change from baseline to week 52 in ACQ score

    Time frame: Up to 52 weeks

  4. Change from baseline in ST. GEORGE'S Respiratory Questionnaire(SGRQ)

    Change from baseline to week 52 in SGRQ score

    Time frame: Up to 52 weeks

  5. Change in pre-bronchodilator forced expiratory volume (FEV1)

    Absolute change from baseline to week 52 in pre-bronchodilator FEV1

    Time frame: Up to 52 weeks

  6. Assessment of adverse events (AEs)

    Number of participants with adverse events (AEs)

    Time frame: Up to 60 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Feb 2027, 32 months after the start.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 32 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2024
First posted
Mar 21, 2024
StartActual
Jun 24, 2024
Primary completionEst.
Feb 2027
CompletionEst.
Sep 2027
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06323213
Responsible party
Sponsor
First posted
Mar 21, 2024
Start date
Jun 24, 2024
Primary completion
Feb 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jan 7, 2026

Study contacts

Qinghong Zhou, MD
Contact
zhouqinghong@3sbio.com
+86 18911301578
Min Zhang
principal investigator · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Xin Zhou
principal investigator · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion